Non-carriers | Unimpaired Carriers | Impaired carriers | Full sample | |
---|---|---|---|---|
N | 15 | 11 | 3 | 29 |
Imaging sessions Baseline | 18-24mo. | 42-48mo. | 15 | 13 | 4 | 11 | 11 | 5 | 3 | 2 | 1 | 29 | 26 | 10 |
Cognitive testing sessions Baseline | 18-24mo. | 42-48mo. | 15 | 15 | 4 | 11 | 10 | 5 | 3 | 3 | 1 | 29 | 28 | 10 |
Total follow-up time (Y) | 2.33 ± 0.97 [1.61-4.33] | 2.82 ± 1.09 [1.85-4.33] | 2.40 ± 1.05 [1.61-3.59] | 2.52 ± 1.01 [1.61-4.33] |
Baseline age (Y) | 39.2 ± 5.9 [28.5-50.2] | 37.3 ± 5.0 [28.5-43.5] | 44.5 ± 1.9 [42.5-46.2] | 39.0 ± 5.6 [28.5-50.2] |
Females, N (%) | 10 (66.7) | 7 (63.6) | 3 (100.0) | 20 (69.0) |
Education (Y) | 9.3 ± 4.4 [2-16] | 9.5 ± 4.8 [2-17] | 13.3 ± 2.5 [11-16] | 9.8 ± 4.5 [2-17] |
Baseline MMSE | 29.3 ± 0.7 [28-30] | 28.0 ± 1.2 [26-30] | 24.3 ± 5.5 [18-28] | 28.3 ± 2.3 [18-30] |